HBOT Conversations:
Robert Beckman & NBIRR Study
Robert Beckman, Ph.D., Founder of the TreatNow Coalition in Arlington, Virginia, discusses the National Brain Injury Rescue Rehabilitation study focused on the use of Hyperbaric Oxygen Therapy for brain injuries. Beckman has a passion for data and helping veterans, which is what ultimately got him first involved in Hyperbaric Oxygen Therapy back in 2008. He was one of many, participating with an elite group of doctors and HBOT experts, who organized and oversaw the results of NBIRR, a multi-center HBOT trial for mild traumatic brain injury with post-concussive symptoms.
The TreatNow Coalition’s Mission is to Stop service member suicides by identifying and treating veterans and others suffering from brain wounds, TBI, PTSD, and Concussion.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with guest, Robert Beckman, founder of Treatnow.org, who was instrumental in the compilation and release of The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms.
It took over a decade for that study to be completed and published. Once it was, it not only opened a door for veterans and others who were looking for a way to heal from head trauma, the NBIRR study ignited other studies to start, focusing solely on the safety & efficacy of Hyperbaric Oxygen Therapy for brain injuries.
Beckman discusses some of the challenges he has witnessed over the years, including the Army declaring that HBOT does not work. After combing through the data, Beckman states that their analysis is rooted in a “lie” about the sham they used in their study; everyone got better. This starts an in-depth conversation between di Girolamo and Beckman about the frustration of the government so easily dismissing HBOT, inflammation linked to PTSD, the stigma of PTSD being a personal and not a physical problem, the disappointment that most veterans don’t even know HBOT exists, and why more is not being done to heal our veterans from these invisible injuries of war.
Beckman proudly states that what started as nine clinics to treat veterans under the NBIRR study, has grown to about 135 clinics across the country that specialize in treating veterans with HBOT for free or reduced rates. Additionally, there are now a combined 12,500-plus success stories from these 135 clinics of individuals with TBI, PTSD, and mTBI who have completed 40 treatments/dives.
Beckman gives surgical statistics relating to HBOT and explains that by pre-oxygenating and post-oxygenating via hyperbaric chambers, patients can benefit from a 30-40% faster healing rate. He points out that countless professional athletes are now using hyperbaric oxygen therapy for faster recuperation to treat pain, injuries, and inflammation; and hyperbarics is being used all over the world right now for successfully treating COVID long-haulers. He states that COVID long-haulers are hypoxic suffering patients, and data exists that military personnel who have experienced the blow of an IUD are suffering in much of the same manner – it’s that lack of oxygen to the brain and all parts of the suffering body that HBOT helps.
di Girolamo asks the question so many of us are curious about, “If HBOT obviously works, why isn’t the military admitting to this? Why aren’t we using it more?” Beckman suggests we read this particular blog on his website that sheds much light on the subject, The Obvious Question: If HBOT works, why aren’t we using it?
Beckman reminds di Girolamo – and all of us – that this is a marathon. Yes, they’ve made great strides over the past two decades in education and research for hyperbaric oxygen therapy, but they still have a way to go. He continues to be optimistic that one day we’ll all witness our shared goal of eliminating the suicide epidemic by utilizing HBOT to thoroughly heal brain injuries.
Guest
Robert L. Beckman, Ph.D.
Dr. Beckman has been building knowledge management systems most of his professional career, primarily in the Intelligence Community and DOD. He is currently helping to run the Clinical Trial researching TBI and PTSD in brain-injured wounded warriors. He is responsible for sustaining the national network of hyperbaric clinics as well as improving the technology platform for data collection and analysis. He is a former USAF KC-135 pilot and a Vietnam Veteran.
TreatNow.org
(571) 549-4258
beckmanr88@gmail.com
Contact TreatNow.org
https://treatnow.org/
Subscribe Now, It’s Free !
Recent HBOT News
The Effect of Hyperbaric Oxygen Therapy on Myocardial Perfusion after the Implantation of Drug-Eluting Stents.
Abstract: The study is to investigate hyperbaric oxygen therapy (HBOT) on myocardial perfusion of patients after the implantation of drug-eluting stents (DES) METHODS: From December 2013 to December 2015, a total of 115 patients with CAD who received DES implantation...
Clinical Trial – Influence of Injection Rate of Intrathecal Mixture of Local Anesthesia on Hypotension in Cesarean Section
Hypotension is the most common complication of neuraxial anesthesia in obstetric patients and
its prevalence in cesarean section is about 50-90%. Maternal hypotension causes unpleasant
symptoms such as nausea, vomiting, loss of consciousness, respiratory depression, and cardiac
arrest. Hypotension may reduce placental perfusion and result in fetal acidosis and
neurological injury. Several techniques have been proposed to prevent hypotension.
The recommended spinal block height to ensure patient comfort for Cesarean delivery is T4-6.
Clinically, it is desirable that the spread of local anesthetic through the cerebrospinal
fluid (CSF) achieves a sensory level no higher than the T4 dermatome to avoid extensive
sympathetic block. It is also important that the spinal block level be no lower than T6 to
avoid patient discomfort during peritoneal manipulation and uterine exteriorization. The
effect of injection speed on spread of spinal anesthesia is controversial. Several studies
have demonstrated more extensive spread with faster injection while others report either
greater spread with slower injection, or no difference. Slow injection of hyperbaric
bupivacaine 10 mg over 60 and 120 sec has been shown to reduce the incidence and severity of
hypotension during Cesarean delivery under spinal anesthesia.
Clinical Trial – Enhanced Recovery After Surgery for Emergency Caesarean Deliveries
Caesarean section (CS) constitutes a large proportion of the total surgical volume in
low-income countries. This rate comes with challenges including surgical complications,
shortage of beds, and consequently long waiting time for operations and high costs. These
have led to the adoption of ERAS in developed countries in a bid to save costs by reducing
hospital length of stay without compromising the health of the mother and her baby.